wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q38884328-CC1E83CC-AB64-42BE-9562-16CD4DE7DBF0
Q38884328-CC1E83CC-AB64-42BE-9562-16CD4DE7DBF0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38884328-CC1E83CC-AB64-42BE-9562-16CD4DE7DBF0
The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib.
P2860
Q38884328-CC1E83CC-AB64-42BE-9562-16CD4DE7DBF0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38884328-CC1E83CC-AB64-42BE-9562-16CD4DE7DBF0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
70a9cd57b34e5c3c826e0ec1def0185f190e81ec
P2860
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.